|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,633.00 JPY | +0.48% |
|
-3.52% | -21.10% |
| 05-18 | US regulator greenlights AstraZeneca's blood pressure drug Baxfendy | AN |
| 05-17 | Daiichi Sankyo, AstraZeneca get US approvals for Enhertu | AN |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 4,525.88 | +75.83% | 17 | ||||||
| 1,210 | +20.41% | 29 | ||||||
| 252.96 | +11.58% | 24 | ||||||
| 252.9 | +20.2% | 29 | ||||||
| 360.76 | +11.76% | 17 | ||||||
| 155.38 | +4.77% | 21 | ||||||
| 221.69 | +22.08% | 21 | ||||||
| 129.74 | +16.48% | 27 | ||||||
| 307.99 | +2.94% | 23 | ||||||
| 352.23 | +7.94% | 30 | ||||||
| 157.96 | +21.9% | 28 | ||||||
| 29.19 | +15.23% | 27 | ||||||
| 62.96 | +10.46% | 25 | ||||||
| 549.29 | +25.71% | 28 | ||||||
| 97.1 | +31.28% | 23 | ||||||
| 20.32 | +9.1% | 20 | ||||||
| 10,096.67 | +27.19% | 15 | ||||||
| 82.08 | +52.02% | 17 | ||||||
| 6,123.53 | +16.04% | 15 | ||||||
| 48.58 | +28.82% | 19 | ||||||
| Average | 1,251.86 | +21.59% | 23 | ||||||
| Weighted average by Cap. | 712.49 | +16.82% | 25 |
- Stock Market
- Equities
- 4568 Stock
- Sector Daiichi Sankyo Company, Limited
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition